Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006  by Jemal, Ahmedin et al.
Recent trends in cutaneous melanoma incidence and
death rates in the United States, 1992-2006
Ahmedin Jemal, DVM, PhD,a Mona Saraiya, MD, MPH,b Pragna Patel, MD, MPH,c Sai S. Cherala, MD, MPH,e
Jill Barnholtz-Sloan, PhD, MS,f Julian Kim, MD,g Charles L. Wiggins, PhD,h and Phyllis A. Wingo, PhDd
Atlanta, Georgia; Concord, New Hampshire; Cleveland, Ohio; and Albuquerque, New MexicoCME INSTRUCTIONS
Please note this is one article that is part of a 16-article CME supplement. CME credit
should only be claimed after reading the entire supplement which can be accessed
via the ‘‘Melanoma Supplement’’ tab under the ‘‘Collections By Type’’ pulldown
menu on http://www.jaad.org.
This journal supplement is a CME activity (enduring material) co-sponsored by the
American Academy of Dermatology and the Centers for Disease Control and
Prevention and is made up of four phases:
1. Reading of the CME Information (delineated below)
2. Reading all the articles in this supplement
3. Achievement of a 70% or higher on the online Post Test
4. Completion of the CME Evaluation
CME INFORMATION AND DISCLOSURES
Statement of Need:
Healthcareproviders continue tounderreportmelanomaeven thoughcancer reporting
requirements mandate such reporting. Additionally, providers may be unaware of
recent trends and descriptive epidemiology regarding melanoma which includes
the fact that nonwhites have a higher mortality rate from melanoma than do whites.
Target Audience:
Dermatologists, dermatopathologists, general physicians, and public health
professionals.
Accreditation
The American Academy of Dermatology is accredited by the Accreditation Council for
ContinuingMedical Education toprovide continuingmedical education forphysicians.
AMA PRA Credit Designation
The American Academy of Dermatology designates this enduring material for a
maximumof 7AMAPRACategory 1 Credits. Physicians should claim only the credit
commensurate with the extent of their participation in the activity.
AAD Recognized Credit
This CME activity is recognized by the American Academy of Dermatology for 7 AAD
Recognized Credits and may be used toward the American Academy of
Dermatology’s Continuing Medical Education Award.
Disclaimer:
The American Academy of Dermatology is not responsible for statements made by
the author(s). Statement or opinions expressed in this activity reflect the views of the
author(s) and do not reflect the official policy of the American Academy of
Dermatology. The information provided in this CME activity is for continuing
education purposes only and is not meant to substitute for independent medical
judgment of a health provider relative to the diagnostic, management and treatment
options of a specific patient’s medical condition.
Disclosures
Editors
The editors involved with this CME activity and all content validation/peer reviewers
of the CME activity have reported no relevant financial relationships with commercial
interest(s).
Authors
The authors of this CME activity have reported no relevant financial relationships
with commercial interest(s).
Planners
The planners involved with this CME activity have reported no relevant financial
relationships with commercial interest(s). The editorial and education staff involved
with this CME activity have reported no relevant financial relationships with
commercial interest(s).
Resolutions of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support of CME, the
American Academy of Dermatology has implemented mechanisms, prior to the
planning and implementation of this CME activity, to identify and mitigate conflits of
interest for all individuals in a position to control the content of this CME activity.
Learning Objectives
After completing this learning activity, participants should be able to describe recent
trends in the epidemiologic patterns of melanoma, including ethnic disparities in
melanoma mortality; identify when a private practice dermatologist is required to
report melanoma cases to a cancer registry; locate and access central cancer reporting
registries (http://apps.nccd.cdc.gov/cancercontacts/npcr/contacts.asp); and recog-
nize and access national and state-based sources on surveillance systems for sun
protection behaviors.
Date of release: November 2011
Expiration date: November 2014
 2011 by the American Academy of Dermatology, Inc.
doi:10.1016/j.jaad.2011.04.032
Technical requirements:
American Academy of Dermatology:
d Supported browsers: FireFox (3 and higher), Google Chrome (5 and higher),
Internet Explorer (7 and higher), Safari (5 and higher), Opera (10 and higher).
d JavaScript needs to be enabled.
Elsevier:
Technical Requirements
This website can be viewed on a PC or Mac. We recommend a minimum of:
d PC: Windows NT, Windows 2000, Windows ME, or Windows XP
d Mac: OS X
d 128MB RAM
d Processor speed of 500MHz or higher
d 800x600 color monitor
d Video or graphics card
d Sound card and speakers
Provider Contact Information:
American Academy of Dermatology
Phone: Toll-free: (866) 503-SKIN (7546); International: (847) 240-1280
Fax: (847) 240-1859
Mail: P.O. Box 4014; Schaumburg, IL 60168
Confidentiality Statement:
American Academy of Dermatology: POLICY ON PRIVACY AND
CONFIDENTIALITY
Privacy Policy - The American Academy of Dermatology (the Academy) is
committed to maintaining the privacy of the personal information of visitors to its
sites. Our policies are designed to disclose the information collected and how it will
be used. This policy applies solely to the information provided while visiting this
website. The terms of the privacy policy do not govern personal information
furnished through any means other than this website (such as by telephone or
mail).
E-mail Addresses and Other Personal Information - Personal information such
as postal and e-mail address may be used internally for maintaining member records,
marketing purposes, and alerting customers or members of additional services
available. Phone numbers may also be used by the Academy when questions about
products or services ordered arise. The Academy will not reveal any information
about an individual user to third parties except to comply with applicable laws or
valid legal processes.
Cookies - A cookie is a small file stored on the site user’s computer orWeb server and
is used to aid Web navigation. Session cookies are temporary files created when a
user signs in on the website or uses the personalized features (such as keeping track
of items in the shopping cart). Session cookies are removed when a user logs off or
when the browser is closed. Persistent cookies are permanent files and must be
S17.e1
deleted manually. Tracking or other information collected from persistent cookies or
any session cookie is used strictly for the user’s efficient navigation of the site.
Links - This site may contain links to other sites. The Academy is not responsible for
the privacy practices or the content of such websites.
Children - This website is not designed or intended to attract children under the age
of 13. The Academy does not collect personal information from anyone it knows is















J AM ACAD DERMATOL
NOVEMBER 2011
S17.e2 Jemal et alBackground: Increasing cutaneous melanoma incidence rates in the United States have been attributed to
heightened detection of thin (# 1-mm) lesions.Objective: We sought to describe melanoma incidence and mortality trends in the 12 cancer registries
covered by the Surveillance, Epidemiology, and End Results program and to estimate the contribution of
thin lesions to melanoma mortality.Methods: We used joinpoint analysis of Surveillance, Epidemiology, and End Results incidence and
mortality data from 1992 to 2006.Results: During 1992 through 2006, melanoma incidence rates among non-Hispanic whites increased for
all ages and tumor thicknesses. Death rates increased for older ([65 years) but not younger persons.
Between 1998 to 1999 and 2004 to 2005, melanoma death rates associated with thin lesions increased and
accounted for about 30% of the total melanoma deaths.Limitations: Availability of long-term incidence data for 14% of the US population was a limitation.Conclusions: The continued increases in melanoma death rates for older persons and for thin lesions
suggest that the increases may partly reflect increased ultraviolet radiation exposure. The substantial
contribution of thin lesions to melanoma mortality underscores the importance of standard wide excision
techniques and the need for molecular characterization of the lesions for aggressive forms. ( J Am Acad
Dermatol 2011;65:S17.e1-11.)
Key words: incidence; melanoma; mortality; SEER (Surveillance, Epidemiology, and End Results); tumor
thickness.Abbreviations used:
AAD: American Academy of Dermatology
APC: annual percent change
RR: rate ratio
SEER: Surveillance, Epidemiology, and End
ResultsCutaneous melanoma (hereafter called mela-
noma) incidence rates continue to increase rapidly
in both men and women in the United States, with
over 95% of the burden occurring in non-Hispanic
white men and women.1 Although many studies
consider this as a true increase,2-5 others attribute it
to an artifact of detecting thin (biologically benign)
lesions as a result of increased diagnostic scru-
tiny.6,7 We examined contemporary melanoma
incidence and mortality patterns for non-HispanicSurveillance Research, American Cancer Society, Atlantaa;
idemiology and Applied Research Branch, Division of
ancer Prevention and Control,b Division of HIV/AIDS Preven-
n,c and Division of Reproductive Health, National Center for
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isease Control and Prevention, Atlanta; Office of Health
atistics and Data Management, Division of Public Health
rvices, New Hampshire Department of Health and Human
rvicese; Case Comprehensive Cancer Center, Case Western
niversity, School of Medicine, Clevelandf; Division of Surgical
ncology, University Hospitals Ireland Cancer Center,
levelandg; and New Mexico Tumor Registry, University of
ew Mexico.hwhites by sex, age, and tumor thickness (incidence
only). Further, we assessed the contribution of thinPublication of this supplement to the JAAD was supported by the
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death rates.
METHODS
We obtained incidence data for invasive mela-
noma diagnosed from 1992 to 2006 from 12 cancer
registries that participate in the Surveillance,CAPSULE SUMMARY
d We observed an increase in melanoma
incidence rates among non-Hispanic
whites that involved all age groups and
tumor thickness categories, including
lesions thicker than 4 mm; melanoma
death rates increased in men and
women aged 65 years or older.
d Thin melanoma may account for about
30% of melanoma deaths.
d There is greater need for targeted clinical
scrutiny of older non-Hispanic white men
for whom the melanoma burden is the
largest and the trend is least favorable.Epidemiology, and End
Results (SEER) program of
the National Cancer Insti-
tute.8 These registries in-
clude Oakland and San
Francisco, San Jose, and Los
Angeles, CA; Seattle, WA;
Detroit, MI; Atlanta, GA; rural
Georgia; Connecticut; Iowa;
New Mexico; Utah; and
Hawaii, and cover about
14% of the US population.
They routinely collect data
on patient demographics,
primary tumor site, tumor
morphology and stage at di-
agnosis, first course of treat-
ment, and follow-up for vital
status. We categorized mela-
noma cases according to sex, age at diagnosis (all
ages, 15-39, 40-64, and $ 65 years), and thickness of
lesion (# 1, 1.01-2.0, 2.01-4.0, and[4.0 mm). SEER
data were also used to calculate mortality by thick-
ness of lesion using incidence-based mortality data
from SEER 9 areas only.9
Melanomamortality data for the corresponding 12
SEER areas and time interval (1992-2006) were
obtained from SEER mortality database as classified
and compiled by the National Center for Health
Statistics, Centers for Disease Control and
Prevention.10 Mortality from melanoma was classi-
fied as 172, according to the International
Classification of Disease, Ninth Revision coding rules
for 1992 to 1998 mortality data and as C43 according
to the International Statistical Classification of
Disease, 10th Revision coding rules for the 1999 to
2006mortality data.11,12 Similar to the incidence data,
we categorized melanoma deaths according to sex
and age. We considered incidence and mortality data
beginning in 1992, the first year when both incidence
and mortality data by Hispanic origin became
available.
Statistical analysis
Trends in melanoma incidence rates from 1992 to
2006 were described using joinpoint regression
analysis for each category of tumor thickness and
age group by sex.13 We similarly examined themortality trend for each age group by sex. The
joinpoint model involves fitting a series of joined
straight lines on a log scale to the trends in the annual
age-standardized rates. The trends for the varying
time periods were described by annual percent
change (APC), ie, the slope of the line segment.
The method is described in detail elsewhere.13 APCvalues that were statistically
significantly different from
zero were interpreted as ev-
idence of temporal change in
the incidence or death rates
in the observed direction of
the APC value. Nonstatisti-
cally significant APC values
were generally interpreted as
evidence of stability in the
incidence or death rates over
the specified time period. We
also tested for differences in
the trends between men and
women within each age
group. We used the Tiwari
method to examine the bur-
den of melanoma (incidence
and mortality) in malescompared with females over two time intervals
(1992-1996 and 2002-2006) by calculating rate ratios
and their 95% confidence intervals.
Partitioning melanoma mortality by thickness of
lesions at diagnosis and other tumor characteristics
can provide insight into the biological significance of
lesions. The incidence-based mortality data from 9
SEER areas allow such analyses.9 Using these data,
we partitioned melanoma deaths that occurred dur-
ing 1998 to 2005 for whites according to categories of
tumor thickness at diagnosis (# 1, 1.01-2.0, 2.01-3.0,
and[4.0 mm) based on cases diagnosed from 1988
through 2005. We examined melanoma cases diag-
nosed beginning in 1988 because this was the first
year in which measurements onmelanoma thickness
were publicly available in the SEER database.
We restricted this analysis to melanoma deaths
recorded beginning in 1998 to insure that melanoma
deaths occurring in each tumor thickness analysis
year (1998-2006) were based on cases diagnosed
over the preceding 10 years,14 as survival for mela-
noma continues to decline throughout the 10 years
after diagnosis.1 Further, we analyzed the incidence-
based mortality data for whites, not for non-Hispanic
whites, because information on Hispanic ethnicity is
not available in the incidence-based mortality data-
base from SEER.
In a supplemental analysis, we also examined the
mortality trend nationally from 1992 through 2006 for
Table I.Melanoma incidence and death rates (2002-2006) and trends (1992-2006) by age and sex, non-Hispanic
whites in Surveillance, Epidemiology, and End Results areas
Sex Age, y
Rate (2002-2006) Rate ratio Trend 1 Trend 2 Trend 3
Rate 95% CI RR 95% CI Year APC Year APC Year APC
Incidence Female All 22.7 22.3-23.0 1.0 1992-2006 3.4*
Male All 33.2 32.7-33.7 1.5 1.4-1.5 1992-2006 3.1*
Female 15-39 16.5 15.9-17.1 1.0 1992-2006 3.6*
Male 15-39 9.7 9.2-10.1 0.6 0.6-0.6 1992-2006 2.0*
Female 40-64 34.0 33.2-34.8 1.0 1992-2006 3.0*
Male 40-64 43.5 42.6-44.4 1.3 1.2-1.3 1992-2006 1.8*
Female $ 65 50.6 49.1-52.1 1.0 1992-2006 3.8*
Male $ 65 130.1 127.4-132.9 2.6 2.5-2.7 1992-2006 4.6*
Mortality
Female All 2.0 1.9-2.1 1.0 1992-2006 0.6*
Male All 4.8 4.6-5.0 2.4 2.2-2.5 1992-1996 2.8 1996-2001 2.0 2001-2006 3.3*
Female 15-39 0.5 0.4-0.6 1.0 1992-2006 2.8*
Male 15-39 0.7 0.6-0.8 1.4 1.1-1.9 1992-2006 3.1*
Female 40-64 2.5 2.3-2.8 1.0 1992-2006 1.6*
Male 40-64 5.0 4.7-5.4 2.0 1.8-2.2 1992-2006 1.6*
Female $ 65 8.6 8.0-9.2 1.0 1992-2006 0.7
Male $ 65 23.7 22.5-24.9 2.8 2.5-3.0 1992-1996 6.6* 1996-2001 1.8 2001-2006 6.4*
Rates are per 100,000 and are age-adjusted to 2000 US standard population.
Incidence rates and mortality are based on data from 12 Surveillance, Epidemiology, and End Results registry areas (Atlanta, GA; rural
Georgia; San Francisco-Oakland, San-Jose-Monterey, and Los Angeles, CA; Connecticut; Detroit, MI; Hawaii; Iowa; New Mexico; Seattle-Puget
Sound, WA; and Utah) covering 14% of US population.
Trends between males and females were statistically different in all age groups.
APC, Annual percent change in age-standardized rates based on joinpoint analyses; CI, confidence interval; RR, rate ratio.
*APC is statistically significant, P\ .05.
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data from 9 states (Connecticut, Maine, Maryland,
Minnesota, New Hampshire, New York, North
Dakota, Oklahoma, Vermont) and Washington, DC.
Data from these regions were excluded because
information on Hispanic origin in medical records or
death certificate was considered unreliable in at least
one of the data years (1992-2006).15
RESULTS
Rates and trends by sex and age
During 2002 through 2006, melanoma rates in
non-Hispanic white men were 50% higher than in
non-Hispanic white women for incidence and more
than double for mortality in the 12 SEER areas
(Table I). By age, the men-to-women rate ratio (RR)
ranged from 1.3 (95% confidence interval, 1.2-1.3) for
ages 40 to 64 years for incidence to 2.6 (2.5-2.7) for
persons at least 65 years old for both incidence and
mortality. The only exception to this pattern is the
lower incidence rates in men than in women (RR =
0.6) aged 15 to 39 years.
Overall incidence rates in the 12 SEER areas
increased for both men and women, whereas death
rates increased in men but decreased in women
(Fig 1 and Table I). For both men and women, death
rates generally decreased among persons youngerthan 65 years, whereas they increased among per-
sons who were 65 years and older although they
were statistically significant only in men. In contrast
to the mortality trends, incidence rates increased for
all age groups in both men and women during 1992
to 2006. The mortality trends based on the national
data were generally similar to those in the 12 SEER
areas (Table II).
Trends by tumor thickness
Melanoma incidence rates increased for all tumor
thicknesses among non-Hispanic whites, although
the rates of increase varied by sex and age (Fig 2 and
Table III). Among men, incidence rates increased for
all thickness categories for those aged 65 years and
older, but only for thin tumors for younger men. In
contrast, among women, incidence rates increased
for all tumor thickness categories for all ageswith two
exceptions-large tumors ([2 mm) among women
aged 40 to 64 years and tumors with thickness of 2.01
to 4.0 mm among women younger than 40 years.
Notably, for older ($ 65 years) men and women,
rates for thick tumors increased nearly as much as for
thin tumors. The higher incidence rate inwomen than
men aged 15 to 39 years was confined to thin lesions.
Conversely, rates for thick lesions were twice as high
in men as in women in this age interval.
Fig 1. Trends in melanoma incidence and death rates by sex and age, non-Hispanic whites, 12
Surveillance, Epidemiology, and End Results (SEER) areas, 1992 to 2006. Rates are per 100,000
and age-adjusted to 2000 US standard population.Dots represent observed rates, and solid lines
represent fitted rates. Asterisks after age groups indicate statistically significant trends, P\ .05.
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Table II. Melanoma incidence and death rates (2002-2006) and trends (1992-2006) by age and sex, non-
Hispanic whites
Sex Age, y
Rate (2002-2006) Rate ratio Trend 1 Trend 2 Trend 3
Rate 95% CI RR 95% CI APC APC APC
SEER incidence Female All 22.7 22.3-23.0 1.0 1992-2006 3.4*
Male All 33.2 32.7-33.7 1.5 1.4-1.5 1992-2006 3.1*
Female 15-39 16.5 15.9-17.1 1.0 1992-2006 3.6*
Male 15-39 9.7 9.2-10.1 0.6 0.6-0.6 1992-2006 2.0*
Female 40-64 34.0 33.2-34.8 1.0 1992-2006 3.0*
Male 40-64 43.5 42.6-44.4 1.3 1.2-1.3 1992-2006 1.8*
Female $ 65 50.6 49.1-52.1 1.0 1992-2006 3.8*
Male $ 65 130.1 127.4-132.9 2.6 2.5-2.7 1992-2006 4.6*
US mortality
Female All 2.1 2.1-2.2 1.0 1992-2006 0.1
Male All 4.8 4.8-4.9 2.3 2.2-2.3 1992-2006 0.5*
Female 15-39 0.5 0.5-0.6 1.0 1992-2006 2.3*
Male 15-39 0.8 0.7-0.8 1.5 1.4-1.7 1992-2001 4.0* 2001-2006 2.2
Female 40-64 2.8 2.7-2.8 1.0 1992-2006 0.7*
Male 40-64 5.5 5.4-5.6 2.0 2.0-2.1 1992-2006 1.0*
Female $ 65 8.7 8.5-8.9 1.0 1992-2006 0.8*
Male $ 65 22.8 22.4-23.2 2.6 2.5-2.7 1992-1998 2.9* 1998-2002 0.8 2002-2006 4.4*
Rates are per 100,000 and are age-adjusted to 2000 US standard population.
Incidence rates are based on data from 12 SEER cancer registries (Atlanta, GA; rural Georgia; San Francisco-Oakland, San-Jose-Monterey, and
Los Angeles, CA; Connecticut; Detroit, MI; Hawaii; Iowa; New Mexico; Seattle-Puget Sound, WA; and Utah) covering 14% of US population.
Death rates are based on data from 41 states, covering 86% of US population. Data from Connecticut, Maine, Maryland, Minnesota, New
Hampshire, New York, North Dakota, Oklahoma, Vermont, and Washington, DC were excluded because information about Hispanic ethnicity
on death certificate was not complete in one of the years (1992-2006) included in analyses.
Rate ratio: rates in males are compared with females by age.
APC, Annual percent change in age-standardized rates based on joinpoint analyses; CI, confidence interval; RR, rate ratio; SEER, Surveillance,
Epidemiology, and End Results.
*APC is statistically significant, P\ .05.
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Between 1998 to 1999 and 2004 to 2005, mela-
noma death rates (per 100,000) among white men
significantly increased from 0.56 (95% confidence
interval, 0.45-0.68) to 0.90 (0.77-1.04) for less than or
equal to 1-mm lesions (thin lesions), but remained
unchanged for the other thickness categories: from
0.54 (0.44-0.66) to 0.65 (0.54-0.77) for 1.01- to
2.0-mm lesions, from 0.64 (0.52-0.76) to 0.77
(0.65-0.90) for 2.01- to 4.0-mm lesions, and from
0.59 (0.48-0.72) to 0.62 (0.51-0.74) for greater than
4-mm lesions (thick lesions). In contrast to men,
melanoma death rate in women did not change for
any of tumor thickness categories: from 0.30
(0.23-0.38) to 0.29 (0.23-0.37) for less than or equal
to 1-mm lesions, from 0.30 (0.23-0.39) to 0.30
(0.24-0.38) for 1.01- to 2.0-mm lesions, from 0.31
(0.25-0.40) to 0.24 (0.19-0.31) for 2.01- to 4.0-mm
lesions, and from 0.16 (0.11-0.22) to 0.23 (0.18-0.30)The 12 SEER areas include Atlanta, GA; rural
Monterey, and Los Angeles, CA; Connecticut; De
Puget Sound, WA; and Utah, and cover about 14%for greater than or equal to 4-mm lesions. Overall,
between 1988 to 1999 and 2004 to 2005, the propor-
tion of melanoma deaths with known tumor thick-
ness that were attributed to thin lesions increased
from 24% to 31% in men and remained unchanged
(27%) in women.
DISCUSSION
Melanoma rates continue to increase among non-
Hispanic white men and women in the United States.
Death rates increased for 65 years or above, and
incidence rates increased for all age groups and
tumor thickness categories, although the increase in
incidence rates for the thickest lesions ([4.0 mm)
was largely confined to age 65 years or older.
Notably, melanoma death rates associated with thin
lesions at diagnosis among white men increased by
60% between 1998 to 1999 and 2004 to 2005, and
they accounted for about 30% of the deaths withGeorgia; San Francisco-Oakland, San-Jose-
troit, MI; Hawaii; Iowa; Kentucky; Seattle-
of US population.
Fig 2. Trends in melanoma incidence rates by sex, age, and tumor thickness, non-Hispanic
whites, 12 Surveillance, Epidemiology, and End Results (SEER) areas, 1992 to 2006. Rates are
per 100,000 and age-adjusted to 2000 US standard population. Dots represent observed rates,
and solid lines represent fitted rates. Asterisks after tumor thickness indicate statistically
significant trends, P\.05. The 12 SEER areas include Atlanta, GA; rural Georgia; San Francisco-
Oakland, San-Jose-Monterey, and Los Angeles, CA; Connecticut; Detroit, MI; Hawaii; Iowa;
New Mexico; Seattle-Puget Sound, WA; and Utah, and cover about 14% of US population.
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2005 in both white men and women.
Factors that may have contributed to the contin-
ued increase in melanoma incidence rates in non-
Hispanic whites include increases in natural (sun)
and artificial (sunbed) ultraviolet radiation exposure,
significant risk factors for melanoma,16-22 and skin
cancer awareness and early detection, although
historical data on these factors are unavailable or
limited. According to two national telephone surveys
that measured changes in sun exposure knowledge,
attitudes, and behaviors between 1986 and 1996
among US adults at least 18 years old, the prevalence
of sunburn increased from 30% to 39% and use of
sunbed from 2% to 6%.23 There is also some evidence
that the use of indoor tanning has increased since the
1990s and its use is not confined to young ages only.
According to more recent data (the 2005 National
Health Interview Survey), the prevalence of indoortanning in the past year ranged from 8% among
persons at least 65 years old to 20% among 18- to 29-
year-olds.24 A similar increase in melanoma rates
among white populations, in part because of greater
intermittent recreational sun exposure, has been
noted in many European countries.25
The American Academy of Dermatology (AAD)
launched a national melanoma/skin cancer educa-
tion program with free skin cancer screening in
1985.26 This effort from AAD and similar efforts from
other public health agencies over the past 20 years
may have contributed to improvements in awareness
of the disease, screening rates, and detection of
lesions at early stage, ie, when they are thin.4,5,26-28
However, contrary to some studies that suggested
these thin lesions are biologically insignificant,6,7 our
data showed that they can be fatal accounting for
about 30% of the total melanoma deaths with known
tumor thickness information in both men and
Table III. Age-standardized rates (2002-2006) and trends (1992-2006) in melanoma incidence rates by age and
tumor thickness among non-Hispanic white males and females
Rate (2002-2006), 95% CI Trend 1 Trend 2
Rate Lower Upper Year APC APC
Male
All ages
All 33.2 32.7 33.7 1992-2006 3.1*
# 1 mm 20.2 19.8 20.5 1992-2006 4.9*
1.01-2.0 mm 4.6 4.5 4.8 1992-2006 2.4*
2.01-4.0 mm 2.9 2.7 3.0 1992-2006 2.9*
[4 mm 1.8 1.7 1.9 1992-2006 4.3*
Unknown 3.2 3.0 3.3 1992-2003 3.0* 2003-2006 12.2*
15-39 y
All 9.7 9.2 10.1 1992-2006 2.1*
# 1 mm 6.4 6.0 6.7 1992-2006 3.3*
1.01-2.0 mm 1.3 1.2 1.5 1992-2006 1.3
2.01-4.0 mm 0.6 0.5 0.7 1992-2006 1.6
[4 mm 0.4 0.3 0.5 1992-2006 2.9
Unknown 0.7 0.6 0.9 1992-2006 5.5*
40-64 y
All 43.5 42.6 44.4 1992-2006 1.8*
# 1 mm 28.3 27.5 29.0 1992-2006 3.6*
1.01-2.0 mm 5.8 5.5 6.2 1992-2006 0.3
2.01-4.0 mm 3.1 2.8 3.3 1992-2006 0.9
[4 mm 1.7 1.6 1.9 1992-2006 1.9
Unknown 3.9 3.6 4.2 1992-2006 5.1*
$ 65 y
All 130.1 127.4 132.9 1992-2006 4.6*
# 1 mm 73.5 71.5 75.6 1992-2006 6.9*
1.01-2.0 mm 18.8 17.8 19.9 1992-2006 4.5*
2.01-4.0 mm 13.5 12.6 14.4 1992-2006 4.3*
[4 mm 8.6 7.9 9.3 1992-2006 5.7*
Unknown 13.6 12.8 14.6 1992-2000 1.3* 2000-2006 6.4*
Female
All ages
All 22.7 22.3 23.0 1992-2006 3.4*
# 1 mm 15.5 15.2 15.8 1992-2006 4.9*
1.01-2.0 mm 2.8 2.7 3.0 1992-2006 2.8*
2.01-4.0 mm 1.3 1.2 1.4 1992-2006 2.0*
[4 mm 0.7 0.7 0.8 1992-2006 3.8*
Unknown 2.1 1.9 2.2 1992-2006 3.5*
15-39 y
All 16.5 15.9 17.1 1992-2006 3.5*
# 1 mm 12.3 11.8 12.8 1992-2006 4.6*
1.01-2.0 mm 1.8 1.6 2.0 1992-2006 3.7*
2.01-4.0 mm 0.6 0.5 0.7 1992-2006 1.4
[4 mm 0.2 0.2 0.3 1992-2006 4.1*
Unknown 1.5 1.3 1.7 1992-2006 2.2*
40-64 y
All 34.0 33.2 34.8 1992-2006 3.0*
# 1 mm 24.5 23.8 25.2 1992-2000 6.1* 2000-2006 2.7*
1.01-2.0 mm 4.1 3.9 4.4 1992-2006 2.2*
2.01-4.0 mm 1.6 1.4 1.8 1992-2006 0.9
[4 mm 0.7 0.6 0.8 1992-2006 1.3
Unknown 2.7 2.5 3.0 1992-2006 4.3*
Continued
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Table III. Cont’d
Rate (2002-2006), 95% CI Trend 1 Trend 2
Rate Lower Upper Year APC APC
$ 65 y
All 50.6 49.1 52.1 1992-2006 3.8*
# 1 mm 29.0 27.9 30.2 1992-2006 5.8*
1.01-2.0 mm 7.1 6.6 7.7 1992-2006 3.0*
2.01-4.0 mm 4.9 4.5 5.4 1992-2006 3.3*
[4 mm 3.3 3.0 3.7 1992-2006 5.3*
Unknown 5.4 5.0 5.9 1992-2006 3.3*
Rates are per 100,000 and age-adjusted to 2000 US standard population.
Incidence data are from 13 Surveillance, Epidemiology, and End Results registries, excluding Alaska Native Registry.
Total counts (number of incidence cases) by tumor thickness do not sum to total because all melanoma cases include those with no mass
(tumors) found.
APC, Annual percent change according to joinpoint analyses; CI, confidence interval.
*APC is statistically significant, P\ .05.
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ing melanoma biologic behavior or less effective
surgical therapy, fueled by the perception that thin
melanomas have an excellent prognosis, is un-
known. There is no information on proportion of
thin melanomas with ulceration, mitoses or regres-
sion, or treatment follow-up for each case in the
SEER database. However, our finding that a substan-
tial proportion of melanoma deaths are associated
with thin lesions underscores the need for continued
emphasis of standard wide excision techniques for
thin melanomas,29 and the importance of research
on molecular characterization of primary cutaneous
melanoma for identifying thin lesions with high risk
of recurrence or metastasis.30 To address the possible
need for selective sentinel lymph node biopsy in
patients with thin melanomas, several groups are
analyzing whether sentinel node biopsy should be
recommended in patients with melanomas between
0.75 and 1 mm.31
Despite the increase in the incidence rates in our
study, the decrease in melanoma death rates for
persons younger than 65 years likely reflects early
detection and improved treatment.4 In this age
interval, the increase in incidence rates was largely
confined to thin lesions. In addition, 5-year relative
survival for younger patients with melanoma (\65
years) who were given a diagnosis between 1992
through 1994 and 2000 through 2005 increased from
89.9% to 93.2%.32 Similar divergence in melanoma
incidence and mortality trends in younger adults has
been reported in several other Western countries.33
In contrast, the increase in melanoma death rates for
those at least 65 years old may reflect higher cumu-
lative lifetime ultraviolet radiation exposure, late
stage at diagnosis, and poor access to medical care
or undertreatment. Notably, incidence rates for thicklesions in older adults continued to increase as
rapidly as for thin lesions.
The higher melanoma burden in men than
women in age groups 40 years and older may reflect
historical differences in chronic sun exposure, dif-
ferent sun-protection practices, skin cancer aware-
ness, and use of early detection services. Men are
more likely than women to have outdoor occupa-
tions and to experience sunburn,23 whereas they are
less likely to conduct skin self-examination,34,35 to
participate in melanoma screening programs,27,36,37
and to practice sun protection.23 However, tanning
bed use is more prevalent in women than men.24
Other suspected host and environmental risk
factors for melanoma include genetic susceptibility,
socioeconomic status, and occupation. The highest
incidence rates of melanoma in the United States and
in other parts of the world are seen in people of
European origin, who have the lightest skin color.38
Melanoma risk is also found to be higher in persons
with higher socioeconomic status than in lower
socioeconomic status,39-41 which may reflect in-
creased opportunity for recreational sun expo-
sures.41 Increased melanoma incidence is also seen
in persons exposed to vinyl chloride and to polyvinyl
chloride.42,43 However, the contributions of these
risk factors to the increasing trends in melanoma
rates in the United States are unknown.
Several limitations in the data may affect the
interpretation of our findings. First, the incidence
rates and trends described here are based on data
from the 12 SEER registries and may not reflect the
national pattern. However, we found that SEER
trends in melanoma death rates were virtually similar
to national trends.
Second, there may be significant variability in the
accuracy of measurement of melanoma thickness
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sites and diagnostic facilities with differing degrees
of experience. Further, the percentage of tumors for
which information on tumor thickness is unknown
has decreased over time. This in part contributes to
the increase in incidence of tumors for which
thickness is specified. After redistribution of un-
known cases proportionately, however, the total
percentage increase in the incidence rates from the
period 1992 though 1994 to the period 2004 through
2006 among non-Hispanic white men decreased,
from 88% to 67% for thin lesions and from 90% to
70% for thick lesions. Similarly, the increase in
melanoma death rates associated with thin lesions
in white men may in part reflect improved recording
of tumor thickness by cancer registries because the
melanoma death rates (per 100,000) attributed to
unknown thickness category decreased from 1.2 in
1998 through 1999 to 0.75 in 2004 through 2005.
However, the improvement in measuring and re-
cording tumor thickness by cancer registries over
the years appeared to be unrelated to disease
severity because the 5-year relative survival for
unknown tumor thickness remained unchanged
(77%) at the beginning and end of the study
intervals of interest. In addition, thin lesions at
diagnosis accounted for about 30% of the melanoma
mortality with known thickness of lesions in both
men and women. Data on follow-up treatment and
diagnostic tests and histology are not available or
incomplete in the SEER database to further charac-
terize these lesions, however; histology information
is missing for nearly 50% (41,426/85,865) of the total
study cases.
Third, the introduction of new disease classifica-
tions could potentially affect mortality trends. Over
the study interval (1992-2006), International
Statistical Classification of Disease, 10th Revision
was implemented beginning with the 1999 mortality
data, replacing the International Classification of
Disease, Ninth Revision that has been used since
1979. About 3% fewer deaths were classified to
melanoma as the underlying cause of death using
International Statistical Classification of Disease,
10th Revision rules as compared with using
International Classification of Disease, Ninth
Revision rules.44 This change could have attenuated
the increase in mortality trends for persons aged 65
years and older. Finally, cancer rates for populations
other than white and black may be limited by
problems in ascertaining race and ethnicity informa-
tion from medical and death certificate records and
census reports.45
In summary, the increasing melanoma death rates
for persons at least 65 years old, the increasingincidence rates for both thin and thick lesions, and
the substantial contribution of thin lesions at diag-
nosis tomelanomamortality together suggest that the
increase in melanoma rates in the United States may
in part reflect increased ultraviolet exposure. Our
findings underscore the need for educational inter-
ventions targeting older non-Hispanic white men on
sunscreen use and other preventive measures for
excessive sun exposure and periodic skin examina-
tion for the early detection of lesions. They also
underscore the importance of standardwide excision
techniques and the need for molecular characteriza-
tion of melanoma lesions for aggressive forms.
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